US2020361932A1PendingUtilityA1
Salts and crystalline forms of an apoptosis-inducing agent
Est. expiryNov 23, 2030(~4.4 yrs left)· nominal 20-yr term from priority
C07D 471/04A61K 31/437A61P 35/02A61K 31/496A61P 37/00A61P 35/00A61P 37/06C07B 2200/13A61P 37/02A61P 43/00A61K 31/4375
74
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . Solid amorphous 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide (Compound 1).
2 . A process for preparing a pharmaceutical formulation comprising combining the solid amorphous Compound 1 of claim 1 with a pharmaceutically acceptable excipient.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.